Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
CytomX Therapeutics, Inc.
Next earnings ≈ Aug 6, 2026 · est. from filing cadence
Last earnings -3.1% on 2026-05-07
Conservative balance sheet (liabilities/equity 0.53x); but revenue fell -44.8% YoY.
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
CytomX Therapeutics, Inc. shows $76.2M in FY2025 revenue (-44.8% YoY), a -22.8% net margin, and -17.5% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro$19/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001501989, latest 10-Q filed 2026-05-07) · EODHD · rules-based read · as of 6/18/2026, 2:27:39 AM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $37.3M | $53.2M | $101M | $138M | $76.2M |
| Gross profit | — | — | — | — | — |
| Operating income | -$116M | -$101M | -$6.48M | $25.0M | -$22.4M |
| Net income | -$116M | -$99.3M | -$569K | $31.9M | -$17.4M |
| Diluted EPS | — | — | — | — | — |
| Net margin | -310.5% | -186.8% | -0.6% | 23.1% | -22.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median
Last 90 days: 0 open-market buys · 1 sale
| 2026-06-15 | Ogden Christopher Chief Financial Officer | Sell | 1.62K @ $3.05 | $4.95K |
| 2026-03-17 | Chu Yu-Waye Chief Medical Officer | Sell | 21.3K @ $6.42 | $137K |
| 2026-03-17 | McCarthy Sean A. CEO | Sell | 119K @ $6.42 | $764K |
| 2026-03-17 | BELVIN MARCIA SVP, Chief Scientific Officer | Sell | 31.5K @ $6.42 | $202K |
| 2026-03-17 | Ogden Christopher Chief Financial Officer | Sell | 19.3K @ $6.42 | $124K |
| 2026-02-02 | Lester Rachael Chief Business Officer | Award | 20.0K | |
| 2026-02-02 | Chu Yu-Waye Chief Medical Officer | Award | 75.0K | |
| 2026-02-02 | BELVIN MARCIA SVP, Chief Scientific Officer | Award | 60.0K |